A phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 modified vaccinia ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)

Trial Profile

A phase 1, placebo-controlled, double-blind study of the safety and immunogenicity of two injections of MVA3000 modified vaccinia ankara (MVA) smallpox vaccine in vaccinia naive adult subjects with a history of atopic dermatitis (AD)

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2014

At a glance

  • Drugs MVA 3000 (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 17 Jan 2014 Planned End Date changed from 1 Sep 2007 to 1 Jan 2007 as per ClinicalTrials.gov record.
    • 07 Jan 2009 Actual end date (Jan 2007) added as reported by ClinicalTrials.gov.
    • 22 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top